Cited by

• Pharmacokinetic and Pharmacodynamic Analyses of 5-Fluorouracil in East-Asian Patients with Nasopharyngeal Carcinoma.

  Ma Y, Lin Y, Zou B, Liu W, Zhang Y, Zhao L, Huang Y, Yang Y, Fang W, Zhao Y, Sheng J, Qin T, Hu Z, Salamone SJ, Li Y, Zhang L, Zhao H. Ma Y, et al. Clin Pharmacokinet. 2016 Oct;55(10):1205-1216. doi: 10.1007/s40262-016-0395-2. Clin Pharmacokinet. 2016. PMID: 27138786 Clinical Trial.
• Pharmacokinetic properties and antitumor efficacy of the 5-fluorouracil loaded PEG-hydrogel.

  Yi H, Cho HJ, Cho SM, Lee DG, Abd El-Aty AM, Yoon SJ, Bae GW, Nho K, Kim B, Lee CH, Kim JS, Bartlett MG, Shin HC. Yi H, et al. BMC Cancer. 2010 May 18;10:211. doi: 10.1186/1471-2407-10-211. BMC Cancer. 2010. PMID: 20482808 Free PMC article.
• A dynamic model of the intestinal epithelium integrates multiple sources of preclinical data and enables clinical translation of drug-induced toxicity.

  Gall L, Jardi F, Lammens L, Piñero J, Souza TM, Rodrigues D, Jennen DGJ, de Kok TM, Coyle L, Chung SW, Ferreira S, Jo H, Beattie KA, Kelly C, Duckworth CA, Pritchard DM, Pin C. Gall L, et al. CPT Pharmacometrics Syst Pharmacol. 2023 Oct;12(10):1511-1528. doi: 10.1002/psp4.13029. Epub 2023 Sep 11. CPT Pharmacometrics Syst Pharmacol. 2023. PMID: 37621010 Free PMC article.
• Kinetically guided neoadjuvant chemoradiotherapy based on 5-Fluorouracil in patients with locally advanced rectal cancer.

  Grim J, Hroch M, Chládek J, Petera J, Martínková J. Grim J, et al. Clin Pharmacokinet. 2015 May;54(5):503-15. doi: 10.1007/s40262-014-0216-4. Clin Pharmacokinet. 2015. PMID: 25503423 Clinical Trial.
• Life-Threatening Reaction with Topical 5-Fluorouracil.

  Kishi P, Price CJ. Kishi P, et al. Drug Saf Case Rep. 2018 Jan 12;5(1):4. doi: 10.1007/s40800-017-0068-6. Drug Saf Case Rep. 2018. PMID: 29330682 Free PMC article.